Eli Lilly has quietly turned a blockbuster obesity and diabetes franchise into one of the market's most intriguing income ...

Eli Lilly is considering all these risks and planning accordingly, and doing so years in advance. That's also why the ...

Eli Lilly (LLY) has shown considerable rally potential, with several occurrences of its stock climbing over 30% in less than ...

Novo Nordisk plans to sell its newly approved obesity pill directly to patients at a lower price than a competing medicine ...

Alpha Wealth Funds, LLC, an investment management company, released its Q3 2025 letter for the “Insiders Fund”. A copy of the ...

With UAB and Southern Research, many have assumed that Birmingham is the state’s life sciences giant, but that thinking may ...

But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study.

Novo Nordisk and Eli Lilly are lowering prices of their top-selling obesity drugs Wegovy and Mounjaro in China, according to ...

Lilly’s return to the JP Morgan Healthcare Conference comes as the company seeks to shift the narrative from last year’s ...

U.S. Olympians Elana Meyers Taylor and Gabby Thomas participated in a social video, drawing a throughline between their ...

Vanda Pharmaceuticals (VNDA) stock rises as the FDA approves its motion sickness therapy Nereus, developed in partnership ...

Eli Lilly stock (NYSE: LLY) is gaining momentum on Thursday, April 17th, following the company’s announcement of successful results from the first of its late-stage trials for a daily obesity pill.